The blockade of central ghrelin receptor can treat NAFLD via the hypothalamic PI3K/Akt/mTOR signaling pathway to improve insulin resistance [134]. The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.